Thursday, March 15, 2018 - 06:55
  • First clinical activity data of the combination of monalizumab and cetuximab
  • New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies
  • Eric Vivier, Chief Scientific Officer, to present at meet-the-expert session on next generation immunotherapies

 

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that new clinical and preclinical data will be presented at the American Association of Cancer Research (AACR) Annual Meeting, taking place from 14 to 18 April 2018 in Chicago.

In particular, preliminary clinical activity data from the ongoing Phase II trial evaluating monalizumab, Innate’s first-in-class antibody targeting inhibitory receptor NKG2A, in combination with cetuximab in previously treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) will be presented.

Eric Vivier, Chief Scientific Officer commented: We have made substantial advances in building a broad and diversified portfolio in immuno-oncology, having the potential to address large unmet medical needs in cancer. We are proud to share data from across this uniquely positioned portfolio and we look ahead to a number of key milestones in 2018.”

Innate will also be sharing new preclinical data on monalizumab, which further supports the rationale for the development of monalizumab as a combination therapy as part of the ongoing joint clinical development program with AstraZeneca/MedImmune. These data demonstrate that blockade of NKG2A potentiates cetuximab induced antibody-dependent cell-mediated cytotoxicity (ADCC) in a preclinical SCCHN model. Separate data suggest the combination of monalizumab and durvalumab as a potent immunotherapy for solid tumors.

Additional highlights from the Innate immuno-oncology portfolio will include preclinical data to support the development of anti-CD39 and anti-CD73 neutralizing antibodies targeting the ATP/Adenosine immune checkpoint pathway for cancer immunotherapy, in combination with chemotherapy or immune checkpoint therapy. CD39 and CD73 are membrane-bound extracellular enzymes which play a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. The blockade of CD39 and CD73 has the potential to promote anti-tumor immune responses across a wide range of tumors. IPH52 (anti-CD39) and IPH53 (anti-CD73) are currently in preclinical development.

Another poster will highlight preclinical findings for a first-in-class antibody program targeting the Siglec-9 immune checkpoint for cancer immunotherapy. This new program has recently been disclosed on Innate Pharma’s R&D Day on March 8.

 

Presentation and poster details have been released on the AACR website and include:

Session Type: Meet-the-Expert Session

Track(s): Immunology, experimental and molecular therapeutics

Session Date and Time: Monday Apr 16, 2018 7:00 AM – 8:00 AM

Location: McCormick Place South, Level 4, Room S406 (Vista Ballroom)

Speaker: Eric Vivier, Chief Scientific Officer, Innate Pharma

 

Session Title: Phase I/II, II, and III Trials in Progress

Session Date and Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM

Location: McCormick Place South, Hall A, Poster Section 42

Poster Board Number 10

Abstract: CT158

 

Session Category: Immunology

Session Title: Immune Checkpoints 1

Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 31

Poster Board Number 15

Abstract: 1690

 

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 6

Abstract: 2714

 

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 10

Abstract: 2718

 

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 5

Abstract: 2713

The posters and presentations will be made available on the Company’s website after the session.

 

AttachmentSize
PR in English88.35 KB
CP en français89.67 KB